The stock of Century Therapeutics Inc (IPSC) has gone up by 0.16% for the week, with a -16.53% drop in the past month and a -38.61% drop in the past quarter. The volatility ratio for the week is 10.18%, and the volatility levels for the past 30 days are 8.60% for IPSC. The simple moving average for the last 20 days is -5.68% for IPSC’s stock, with a simple moving average of -58.28% for the last 200 days.
Is It Worth Investing in Century Therapeutics Inc (NASDAQ: IPSC) Right Now?
IPSC has 36-month beta value of 1.73. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for IPSC is 36.25M, and currently, short sellers hold a 8.47% ratio of that float. The average trading volume of IPSC on February 21, 2025 was 604.82K shares.
IPSC) stock’s latest price update
The stock price of Century Therapeutics Inc (NASDAQ: IPSC) has dropped by -1.24 compared to previous close of 0.76. Despite this, the company has seen a gain of 0.16% in its stock price over the last five trading days. globenewswire.com reported 2024-11-26 that PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) — Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune disease, today announced that members of the management team will participate in the following events at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024:
Analysts’ Opinion of IPSC
Many brokerage firms have already submitted their reports for IPSC stocks, with Rodman & Renshaw repeating the rating for IPSC by listing it as a “Buy.” The predicted price for IPSC in the upcoming period, according to Rodman & Renshaw is $6 based on the research report published on August 08, 2024 of the previous year 2024.
JP Morgan, on the other hand, stated in their research note that they expect to see IPSC reach a price target of $5, previously predicting the price at $28. The rating they have provided for IPSC stocks is “Neutral” according to the report published on August 28th, 2023.
Chardan Capital Markets gave a rating of “Buy” to IPSC, setting the target price at $19 in the report published on December 27th of the previous year.
IPSC Trading at -22.92% from the 50-Day Moving Average
After a stumble in the market that brought IPSC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.41% of loss for the given period.
Volatility was left at 8.60%, however, over the last 30 days, the volatility rate increased by 10.18%, as shares sank -15.95% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -47.63% lower at present.
During the last 5 trading sessions, IPSC rose by +0.16%, which changed the moving average for the period of 200-days by -75.04% in comparison to the 20-day moving average, which settled at $0.7941. In addition, Century Therapeutics Inc saw -25.85% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IPSC starting from Pfeiffenberger Brent, who sale 34,712 shares at the price of $0.78 back on Feb 18 ’25. After this action, Pfeiffenberger Brent now owns 1,192,545 shares of Century Therapeutics Inc, valued at $27,179 using the latest closing price.
Pfeiffenberger Brent, the Officer of Century Therapeutics Inc, proposed sale 34,712 shares at $0.78 during a trade that took place back on Feb 18 ’25, which means that Pfeiffenberger Brent is holding shares at $27,166 based on the most recent closing price.
Stock Fundamentals for IPSC
Current profitability levels for the company are sitting at:
- -49.26 for the present operating margin
- -4.04 for the gross margin
The net margin for Century Therapeutics Inc stands at -48.38. The total capital return value is set at -0.36. Equity return is now at value -62.61, with -33.04 for asset returns.
Based on Century Therapeutics Inc (IPSC), the company’s capital structure generated 0.22 points at debt to capital in total, while cash flow to debt ratio is standing at -2.05.
Currently, EBITDA for the company is -121.21 million with net debt to EBITDA at -0.02. When we switch over and look at the enterprise to sales, we see a ratio of 24.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.39.
Conclusion
To put it simply, Century Therapeutics Inc (IPSC) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
